Zosano Pharma Corporation (NASDAQ:ZSAN) went down by -4.72% from its latest closing price compared to the recent 1-year high of $3.06. The company’s stock price has collected 0.83% of gains in the last five trading sessions. Press Release reported on 03/17/21 that Thinking about buying stock in FSD Pharma, Onconova Therapeutics, Nabriva Therapeutics, Zosano Pharma, or Savara?
Is It Worth Investing in Zosano Pharma Corporation (NASDAQ :ZSAN) Right Now?
Plus, the 36-month beta value for ZSAN is at 3.93. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Zosano Pharma Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $2.25. ZSAN currently public float of 101.70M and currently shorts hold a 8.08% ratio of that float. Today, the average trading volume of ZSAN was 10.28M shares.
ZSAN’s Market Performance
ZSAN stocks went up by 0.83% for the week, with a monthly jump of 1.68% and a quarterly performance of 50.29%, while its annual performance rate touched 128.73%. The volatility ratio for the week stands at 5.36% while the volatility levels for the past 30 days are set at 9.53% for Zosano Pharma Corporation. The simple moving average for the period of the last 20 days is -4.61% for ZSAN stocks with a simple moving average of 18.41% for the last 200 days.
Analysts’ Opinion of ZSAN
Many brokerage firms have already submitted their reports for ZSAN stocks, with Maxim Group repeating the rating for ZSAN by listing it as a “Buy.” The predicted price for ZSAN in the upcoming period, according to Maxim Group is $8 based on the research report published on April 17th of the previous year 2019.
Piper Jaffray, on the other hand, stated in their research note that they expect to see ZSAN reach a price target of $4. The rating they have provided for ZSAN stocks is “Overweight” according to the report published on March 24th, 2017.
ZSAN Trading at -5.89% from the 50-Day Moving Average
After a stumble in the market that brought ZSAN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.46% of loss for the given period.
Volatility was left at 9.53%, however, over the last 30 days, the volatility rate increased by 5.36%, as shares surge +2.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.15% upper at present.
During the last 5 trading sessions, ZSAN rose by +0.83%, which changed the moving average for the period of 200-days by +43.71% in comparison to the 20-day moving average, which settled at $1.2700. In addition, Zosano Pharma Corporation saw 129.56% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ZSAN
Current profitability levels for the company are sitting at:
- -14624.11 for the present operating margin
- -1050.45 for the gross margin
The net margin for Zosano Pharma Corporation stands at -14896.87. The total capital return value is set at -71.61, while invested capital returns managed to touch -84.69. Equity return is now at value -91.90, with -52.20 for asset returns.
Based on Zosano Pharma Corporation (ZSAN), the company’s capital structure generated 35.41 points at debt to equity in total, while total debt to capital is 26.15. Total debt to assets is 23.36, with long-term debt to equity ratio resting at 20.75. Finally, the long-term debt to capital ratio is 15.32.
When we switch over and look at the enterprise to sales, we see a ratio of 77.48, with the company’s debt to enterprise value settled at 0.97. The receivables turnover for the company is 3.61 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.46.